Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) Invested Capital (2023 - 2025)

Historic Invested Capital for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $687.6 million.

  • CG Oncology's Invested Capital rose 2810.76% to $687.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $687.6 million, marking a year-over-year increase of 2810.76%. This contributed to the annual value of $733.4 million for FY2024, which is 69575.71% up from last year.
  • As of Q3 2025, CG Oncology's Invested Capital stood at $687.6 million, which was up 2810.76% from $670.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Invested Capital registered a high of $733.4 million during Q4 2024, and its lowest value of -$123.1 million during Q4 2023.
  • Its 3-year average for Invested Capital is $541.4 million, with a median of $619.6 million in 2024.
  • Its Invested Capital has fluctuated over the past 5 years, first skyrocketed by 69575.71% in 2024, then skyrocketed by 2136.27% in 2025.
  • Over the past 3 years, CG Oncology's Invested Capital (Quarter) stood at -$123.1 million in 2023, then surged by 695.76% to $733.4 million in 2024, then dropped by 6.24% to $687.6 million in 2025.
  • Its last three reported values are $687.6 million in Q3 2025, $670.4 million for Q2 2025, and $704.8 million during Q1 2025.